Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 1
Submit an article Journal homepage
48
Views
3
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for moderate-to-severe psoriasis

Melissa A Magliocco UMDNJ-Robert Wood Johnson Medical School, Clinical Research Center, 51 French Street, New Brunswick, NJ 08901-0019, USA. [email protected]
Pages 35-52 | Published online: 22 Apr 2005

Bibliography

  • TUTRONE WD, KAGEN MH, BARBAGALLO J, WEINBERG JM: Biologic therapy for psoriasis: a brief history, II. Cutts. (2001) 68(6):367–372.
  • Results of the National Psoriasis Foundation 2001 Psoriasis and Psoriatic Arthritis Benchmark Survey. Prepared by Gail Zimmerman, President and CEO National Psoriasis Foundation.
  • LOMHOLT G: Psoriasis: prevalence, spontaneous course and genetics: a census study on the prevalence of skin diseases on the Faroe Islands. Copenhagen, Denmark: GEC GAD, 1963.
  • HENSELER T, CHRISTOPHERS E: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. DermatoL (1985) 13(3):450–456.
  • INTERNATIONAL PSORIASIS GENETICS CONSORTIUM. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am. J. Hum. Genet. (2003) 73(2):430–437.
  • CAPON F, SEMPRINI S, CHIMENTI S et al.: Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J. Invest. Dermatol (2001) 116(5):728–730.
  • BOWCOCK AM, COOKSON WO: The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum. Mol. Genet. (2004) 13 Spec No 1:R43–R55.
  • •An excellent review of the genetics of psoriasis and psoriatic arthritis.
  • FREDRIKSSON T, PETERSSON U: Severe psoriasis — oral therapy with a new retinoid. Dermatologica (1978) 157:238–241.
  • FINLAY AY, KHAN GK: Dermatology LifeQuality Index (DLQI): a simple practical measure for routine clinical use. Clin. Exp. Dermatol. (1994) 19:210–216.
  • BAKER BS, SWAIN AF, VALDIMARSSON H, FRY L: T-cell subpopulations in the blood and skin of patients with psoriasis. Br. J. Dermatol. (1984) 110:37–44.
  • COOPER KD: Skin-infiltrating lymphocytes in normal and disordered skin: activation signals and functional roles in psoriasis and mycosis fungoides-type cutaneous T cell lymphoma. J. Dermatol. (1992) 19:731–737.
  • GOTTLIEB AB: Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J. Invest. Dermatol. Symp. Proc. (2004) 9(1):79–83.
  • •A good review of targeted immunotherapy research in psoriasis.
  • GUPTA MA, SCHORK NJ, GUPTA AK, KIRKBY S, ELLIS CN: Suicidal ideation in psoriasis. Int. J. Dermatol. (1993) 32(3):188–190.
  • RAPP SR, FELDMAN SR, EXUM ML, FLEISCHER AB JR, REBOUSSIN DM: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. (1999) 41(3 Pt 1):401–407.
  • GISONDI P, GUBINELLI E, COCUROCCIA B, GIROLOMONI G: Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy. (2004) 3(2):175–183.
  • VICTOR FC, GOTTLIEB AB, MENTER A: Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol. (2003) 21(5):392–397.
  • VICTOR FC, GOTTLIEB AB: TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J. Drugs Dermatol. (2002) 1(3):264–275.
  • HUGHES J, RUSTIN M: Corticosteroicis. Clin. Dermatol. (1997) 15: 715–721.
  • ASHCROFT DM, PO AL, WILLIAMS HC, GRIFFITHS CE: Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Br. Med. J. (2000) 320(7240):963–967.
  • MICHEL S, JOMARD A, DEMARCHEZ M: Pharmacology of adapalene. Br. J. Dermatol. (1998) 139(Suppl. 52):3–7.
  • SCHWARTZ PM, BARNETT SK, ATILLASOY ES, MILSTONE LM: Methotrexate induces differentiation of human keratinocytes. Proc. Natl Acad. Sci. USA (1992) 89(2)594–598.
  • CATHER J, MENTER A: Novel therapies for psoriasis. Am. J. Clin. Dermatol. (2002) 3(3):159–173.
  • •A good review of biologicals and other therapies for psoriasis.
  • ROENIGK HH, AUERBACH R, MAIBACH H, WEINSTEIN G, LEBWOHL M: Methotrexate in psoriasis: consensus conference. J. Am. Acad. Dermatol. (1998) 38:478–485.
  • ELLIS CN, GORSULOWSKY DC, HAMILTON TA et al.: Cyclosporine improves psoriasis in a double-blind study. JAMA (1986) 256(22):3110–3116.
  • HARPER JI, KEAT AC, STAUGHTON RC: Cyclosporin for psoriasis. Lancet (1984) 2(8409):981–982.
  • GRIFFITHS CE, POWLES AV, MCFADDEN J, BAKER BS, VALDIMARSSON H, FRY L: Long-term cyclosporin for psoriasis.Br. j Dermatol. (1989) 120(2):253–260.
  • BOS JD, MEINARDI MM, VAN JOOST T, HEULE F, POWLES AV, FRY L: Use of cyclosporin in psoriasis. Lancet (1989) 23–30;2(8678–8679): 1500–1502.
  • HEULE F, MEINARDI MM, VAN JOOST T, BOS JD: Low-dose cyclosporine effective in severe psoriasis: a double-blind study. Transplant Proc. (1988) 20(3 Suppl. 4):32–41.
  • WENTZELL JM, BAUGHMAN RD, O'CONNOR GT, BERNIER GM JR: Cyclosporine in the treatment of psoriasis. Arch. Dermatol. (1987) 123(2):163–165.
  • PICASCIA DD, GARDEN JM, FREINKEL RK, ROENIGK HH JR: Treatment of resistant severe psoriasis with systemic cyclosporine. J. Am. Acad. Dermatol. (1987) 17(3):408–414.
  • MEINARDI MM, BOS JD: Cyclosporine maintenance therapy in psoriasis. Transplant Proc. (1988) 20(3 Suppl. 4):42–49.
  • FINZI AF, MOZZANICA N, CATTANEO A, CHIAPPINO G, PIGATTO PD: Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J. Am. Acad. Dermatol. (1989) 21(1):91–97.
  • HEYDENDAEL VM, SPULS PI, OPMEER BC et al.: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl. J. Med. (2003) 349:658–665.
  • KOLBACH DN, NIEBOER C: Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J. Am. Acad. Dermatol. (1992) 27: 769–771.
  • ALTMEYER PJ, MATTHES U, PAWLAK F et al.: Antipsoriatic effect of fumaric acid derivatives. J. Am. Acad. Dermatol. (1994) 30: 977–981.
  • MROWIETZ U, CHRISTOPHERS E, ALTMEYER P: Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br. J. Dermatol. (1998) 138:456–460.
  • NIEBOER C, DE HOOP D, VAN LOENEN AC et al.: Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J. Am. Acad. Dermatol. (1989) 20:601–608.
  • TREUMER F, ZHU K, GLASER R, MROWIETZ U: Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. (2003) 121(6):1383–1388.
  • GHORESCHI K, ROCKEN M: Immune deviation strategies in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy (2004) 3(2):193–198.
  • ROODNAT JI, CHRISTIAANS MH, NUGTEREN-HUYING WM et al: Acute kidney insufficiency in patients treated with fumaric acid esters for psoriasis. Ned Hjdschr. Geneeskd. (1989)133:2623–2626.
  • KOLBACH DN, NIEBOER C: Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J. Am. Acad. Dermatol. (1992) 27: 769–771.
  • ALTMEYER P, HARTWIG, R, MATTHES U: Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory of psoriasis vulgaris. A study of 83 patients. Hautarzt. (1996) 47:190–196.
  • OZAWA M, FERENCZI K, KIKUCHI T: 312-nanometer ultraviolet B light (Narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J. Exp. Med. (1999) 189(4):711–718.
  • •Strong support for apoptosis as the mechanism of action of narrow-band UVB phototherapy.
  • JOHNSON R, STAIANO-COICO L, AUSTIN L, CARDINALE I, NABEYA-TSUKIFUJI R, KRUEGER JG: PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem. PhotobioL (1996) 63(5):566–571.
  • ELLIS CN, KRUEGER GG: Alefacept clinical study group: treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. J. Med. (2001) 345(4):248–255.
  • KRUEGER GG, ELLIS CN: Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol (2003) 148(4):784–788.
  • KRUEGER GG. Clinical response to alefacept: results of a Phase III study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol Venereol (2003) 17(Suppl. 2):17–24.
  • CATHER JC, CATHER JC, MENTER A: Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther. (2003) 3(2):361–370.
  • GOTTLIEB AB, MILLER B, LOWE NJ et al.: Subcutaneously administered efalizumab (anti-CD 11a) improves signs and symptoms of moderate to severe plaque psoriasis. J. Cutan. Med. Surg (2003) Apr 30 (Epub ahead of print).
  • LEBWOHL M, TYPING SK, HAMILTON TK et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl. J. Med. (2003) 349 (21) :2004–2013.
  • MEASE PJ: Current treatment of psoriatic arthritis. Rheum. Dis. Clin. N Am. (2003) 29:495–511.
  • ORY P, SHARP JT, SALONEN D et al: Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis [abstract]. Arthritis Rheum. (2002) 46(Suppl): S196. Abstract 442.
  • ORY P, SHARP JT, SALONEN D et al: Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis. Paper presented at: Annual European Congress of Rheumatology; 30 June (2003) Lisbon, Portugal. Abstract 0P0089.
  • LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N Engl. J. Med. (2003) 349 (21) :2014–2022.
  • GUENTHER L, VAN DE KERKHOF PC, SNELLMAN E et al.: Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle- controlled clinical trial. Br. J. Dermatol (2002) 147(2):316–323.
  • BOWMAN PH, MALONEY JE, KOO JY: Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study./ Am. Acad. Dermatol. (2002) 46(6):907–913.
  • KRUEGER JG: The immunologic basis forthe treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol (2002) 46(1):1–23.
  • MUELLER W, HERMANN B: Cyclosporin A for psoriasis. N Engl. J. Med. (1979) 301:555.
  • BAKER BS, SWAIN AF, FRY L, VALDIMARSSON H: Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br. J. Dermatol (1984) 110:555–564.
  • GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1(5):442–447.
  • VISSERS WH, ARNDTZ CH, MUYS L, VAN ERP PE, DE JONG EM, VAN DE KERKHOF PC: Memory effector (CD45R0*) and cytotoxic (CD8*) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol (2004) 150(5):852–859.
  • BONIFATI C, CARDUCCI M, CORDIALI FEI P et al.: Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin. Exp. Dermatol. (1994) 19(5):383–387.
  • ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol (1994) 96(1):146–151.
  • •Gives clear support for the role of TNF-a in the pathogenesis of psoriasis.
  • PARTSCH G, STEINER G, LEEB BF et al: Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol (1997) 24:518–523.
  • RITCHLIN C, HAAS-SMITH SA, HICKS D et al: Patterns of cytokine production in psoriatic synovium. Rheumatol (1998) 25:1544–1552.
  • DANNING CL, ILLEI GG, HITCHON C et al.: Macrophage-derived cytokine and nuclear factor B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. (2000) 43:1244–1256.
  • GOTTLIEB AB, BOS JD: Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immunol (2002) 105(2):105–116.
  • •A review of biological therapy in psoriasis.
  • CHEN DM, GORDON K, LEONARDI C, MENTER MA: Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. Poster presented at: American Academy of Dermatology 62nd Annual Meeting; February 9, 2004; Washington, DC. Abstract 2.
  • GOTTLIEB AB, MASUD S, RAMAMURTHI R et al.: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. (2003) 48(1):68–75.
  • OH CJ, DAS KM, GOTTLIEB AB: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol (2000) 42(5 Pt 1):829–830.
  • CHAUDHARI U, ROMANO P, MULCAHY LD, DOOLEY LT, BAKER DG, GOTTLIEB AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 9;357(9271):1842–1847.
  • ••Landmark trial that demonstrates theefficacy and safety of infliximab in psoriasis.
  • GOTTLIEB AB, CHAUDHARI U, MULCAHY LD, LI S, DOOLEY LT, BAKER DG: Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. (2003) 48(6):829–835.
  • ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic arthritis with or without concomitant DMARD therapy. Program and abstracts of the Annual European Congress of Rheumatology (EULAR 2003); June 18–21, 2003; Lisbon, Portugal. Abstract 0P0082.
  • Ninth International Psoriasis Symposium; June 18–22, 2003; New York, NY
  • GHORESCHI K, THOMAS P, BREIT S et al.: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. (2003) 9(1):40–46.
  • GHORESCHI K, MROWIETZ U, ROCKEN M: A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J. Mol Med. (2003) 81(8):471–480.
  • ASADULLAH K, DOCKE WD, EBELING M et al.: Interleukin 10 treatment of psoriasis: clinical results of a Phase II trial. Arch. Dermatol. 1999 Feb; 135(2):187–192.
  • ASADULLAH K, STERRY W, STEPHANEK K et al: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. Clin. Invest. (1998) 101(4):783–794.
  • TREPICCHIO WL, OZAWA M, WALTERS TB et al: Interleukin-11 therapy selectively downregulates Type I cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. (1999) 1040 0:1527–1537.
  • KRUEGER GG, BELL GM, HUANG S, et al: ABX-1L8 in the treatment of psoriasis: clinical results. Society for Investigative Dermatology Annual Meeting, May 2002. Poster presentation.
  • YAWALKAR N, KARLEN S, HUNGER R, BRAND CU, BRAATHEN LR: Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol (1998) 111(6):1053–1057.
  • KAUFFMAN CL, ARIA N, TOICHI E et al.: A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol (Epub ahead of print)
  • GOTTLIEB AB, LEBWOHL M, SHIRIN S et al.: Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose placebo-controlled study./ Am. Acad. Dermatol. (2000) 43:595–604.
  • SKOV L, KRAGBALLE K, ZACHARIAE C et al: HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol 2003 Nov; 139(11):1433–1439.
  • GOTTLIEB AB, LEBWOHL M, TOTORITIS MC et al.: Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J. Am. Acad. Dermatol (2002) 47(5):692–700.
  • GOTTLIEB AB, KANG S, LINDEN KG et al.: Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin. Immunol (2004) 111(1):28–37.
  • KRUEGER JG, WALTERS TB, MIYAZAWA M et al.: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J..Am. Acad. Dermatol. (2000) 43(3):448–458.
  • TRAJKOVIC V: Nuvion. Protein Design Labs. Curr. Opin. Investig. Drugs (2002) 3:411–414.
  • LANGLEY R, ROENIGK H, DINGI VAN C: Safety, tolerance, and disease activity of MEDI-507 for the treatment of moderate to severe psoriasis: a review of Phase I results. In: 2nd Joint Meeting International Psoriasis Symposium and European Congress on Psoriasis. 19–24 June, (2001) Plenary 7.
  • LIU V MACKOOL BT: Mycophenolate indermatology. J. Dermatolog. Treat. (2003) 14(4):203–211.
  • GEILEN CC, ARNOLD M, ORFANOS CE: Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br. J. Dermatol (2001) 144(3):583–586.
  • SCHRADER P, MOOSER G, PETER RU, PUHL W: [Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil] Z. RheumatoL (2002) 61(5):545–550.
  • RAPPERSBERGER K, KOMAR M, EBELIN ME et al.: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J. Invest. Dermatol (2002) 119(4):876–887.
  • WOLFF K, STUETZ A: Pimecrolimus forthe treatment of inflammatory skin disease. Expert Opin. Pharmacother. (2004) 5(3):643–655.
  • EUROPEAN FK 506 MULTICENTRE PSORIASIS STUDY GROUP: Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch. Dermatol. (1996) 132: 419–423.
  • ZONNEVELD IM, RUBINS A, JABLONSKA S et al.: Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch. Dermatol. (1998) 134(9):1101–1102.
  • FREEMAN AK, LINOWSKI GJ, BRADY C et al.: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol. (2003) 48(4):564–568.
  • REMITZ A, REITAMO S, ERKKO P, GRANLUND H, LAUERMA Al: Tacrolimus ointment improves psoriasis in a microplaque assay. Br. J. Dermatol (1999) 141(1):103–107.
  • FIORENTINO DF, VOSGANIAN, LEVIN C, KIMBALL AB: A double-blind placebo-controlled randomized parallel dose comparison of topically applied cyclosporine A conjugate (CGC1072) versus vehicle control in psoriasis patients. Program of the 61st Annual Meeting of the American Academy of Dermatology. 22–26 March (2003) San Francisco, California. Poster 590.
  • ELLIS CN, VARANI J, FISHER GJ et al: Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch. Dermatol. (2000) 136(5):609–616.
  • BHAGAVATHULA N, NERUSU KC, LAL A et al: Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J. Invest. Dermatol. (2004) 122(1):130–139.
  • WALKER PS, GOTTLIEB A, GUENTHER L, et al: Oral tazarotene (4.5 mg capsule) in patients with moderate to very severe plaque psoriasis. Poster presented at: American Academy of Dermatology Academy 2003. 25–29 July (2003) Chicago, IL.
  • SMIT JV, FRANSSEN ME, DE JONG EM et al: A Phase II multicenter clinical trial of systemic bexarotene in psoriasis. J. Am. Acad. DermatoL (2004) 51(2):249–256.
  • SMIT JV, DE JONG EM, VAN HOOIJDONK CA, OTERO ME, BOEZEMAN JB, VAN DE KERKHOF PC: Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J. Am. Acad. DermatoL (2004) 51(2):257–264.
  • LEBWOHL M: Advances in psoriasis therapy. DermatoL Clin. (2000)18:13–19.
  • TIWARI SB, KUMAR BCR, UDUPA N, BALACHANDRAN C: Topical methotrexate delivered by iontophoresis in the treatment of recalcitrant psoriasis — a case report. Int. J. DermatoL (2003) 42(2):157–159.
  • KUMAR RBC, INDERJEET K, BHUSHAN K: Topical methotrexate therapy in palmoplantar psoriasis. Indian J. DermatoL Venereolo. Leprolo. (1999) 65(6):270–272.
  • MORROW T: The 'heartbreak of psoriasis' has met its match! Manag Care. (2003) 12(6): 13,17–18.

Websites

  • http://www.aad.org/pamphlets/ Psoriasis.html. Accessed October 2004. American Academy of Dermatology website — Psoriasis Pr(1994).
  • http://www.syntapharma.com/products/ immune.phpSTA5326. Accessed October 2004. Synta Pharmaceuticals Corp. 5TA5326.
  • http://www.pdl.com/applications/ press_releases.cfm?newsId=36. Accessed November 2004. Protein Design Labs — Press Releases.
  • http://www.pvct.com/pharmatech.html. Accessed October 2004. Pharmatech — Provectus Pharmaceuticals, Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.